NCT05833984 2023-04-27
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
Clinical Trials
5 trialsNCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
NCT04539444 2021-08-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT04843267 2021-04-13
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Sun Yat-sen University
Phase 2 Unknown